Clinical study of a new Chinese porous tantalum rod implantation for treatment of early-stage femoral head osteonecrosis

Clinical study of a new Chinese Runze porous tantalum rod implantation for treatment of early-stage femoral head osteonecrosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015182

Enrollment

Unknown

Registered

2018-03-12

Start date

2014-07-22

Completion date

Unknown

Last updated

2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

femoral head osteonecrosis

Interventions

Runze tantalum rod group:Core decompression and Runze tantalum rod implantation

Zimmer tantalum rod group:Core decompression and Zimmer tantalum rod implantation

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 60 years; (2) Body mass index<40; (3) ARCO I, IIA or IIB; (4) Non-traumatic aetiologies; (5) No history of mental illness, drug abuse, systemic disease, infectious diseases, or immune system disorders;

Exclusion criteria

Exclusion criteria: (1) Patients were actively being treated with corticosteroids; (2) A history of previous surgery to the affected hip; (3) Those were unwilling to have surgery at time of clinical presentation.

Design outcomes

Primary

Measure	Time frame
surgical time;blood loss;Harris hip score;complications;radiological progression assessment;hard tissue slicing;Van Gieson staining;	—

Countries

China

Contacts

Public ContactDianming Jiang

The First Affiliated Hospital of Chongqing Medical University

1276321387@qq.com+86 13983836636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026